A phase Ib, proof-of-concept trial of anatabine in patients with mild to moderate psoriasis

Trial Profile

A phase Ib, proof-of-concept trial of anatabine in patients with mild to moderate psoriasis

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Anatabine (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 11 Aug 2016 According to a Rock Creek Pharmaceuticals media release, initiation of this study is likely to be postponed from fourth quarter of 2016 to early first half of 2017.
    • 16 May 2016 According to a Rock Creek Pharmaceuticals media release, the company expects to test therapeutic potential of anatabine in this study in Q4 of 2016.
    • 15 Oct 2015 According to a Rock Creek Pharmaceuticals, Inc. media release, this trial is expected to commence in the first half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top